Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.
Research-use-only status: what it means legally and practically — a second dataset
How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.
Distinguishing marketed research compounds from true chemical synthesis: some online suppliers sell compounds that are genuinely novel and difficult to obtain elsewhere. Others repackage standard compounds. Verifying what you are buying requires careful documentation review.
Worth separating two things that post #36 runs together.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.
I read post #58 twice before replying, because I had assumed the opposite.
This subcategory exists because some people will research compounds outside the main groups discussed here. The standard of evidence and honesty about its limits applies to everything discussed, not just to approved drugs.
Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.
Naming conventions for research peptides cause confusion because suppliers do not follow a standard. The same compound gets different names from different suppliers. If you are researching something, confirming the sequence or mass is more reliable than confirming the name.
Read the full topic (126 posts)
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
About the Other compounds category
Anything not covered by a dedicated subcategory, including research-use-only material with no human data. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
+8 | 12 | 51k | 7mo |
|
Coming back to: When "no data" is the complete and final answer
When "no data" is the complete and final answer I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…
|
+77 | 82 | 12k | 11mo |
|
Sequence verification for an obscure compound: how it is done — what changed since
On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please…
|
+100 | 108 | 1.3k | 8mo |
|
Research-use-only status: what it means legally and practically
Research-use-only status: what it means legally and practically Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…
|
+72 | 81 | 44k | 1d |
|
AOD-9604 and the fragment hypothesis, revisited
Posting this under the heading it deserves: AOD-9604 and the fragment hypothesis, revisited Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with SUSTAIN 6 ( N Engl J Med…
|
+40 | 44 | 2.8k | 6mo |
Related topics — sharing the tags research use only, mislabelling, needs a source
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Revisiting: Why a compound being unapproved is not the same as being illegal to possess
On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. Structured report rather than an opinion, following…
|
+76 | 82 | 52k | 11mo |
|
Labelling requirements for research chemicals — the long version
Posting this under the heading it deserves: Labelling requirements for research chemicals — the long version Everything below is what sits behind that. I would like to talk about documentation quality as a…
|
2 | 1.8k | 2mo | |
|
Follow-up: Evidence quality in the secretagogue literature: an honest assessment
On the subject in the title: Evidence quality in the secretagogue literature: an honest assessment Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with LEADER ( N Engl J Med…
|
+20 | 24 | 18k | 4mo |
|
Reading a supplier's product description as a marketing document
On the subject in the title: Reading a supplier's product description as a marketing document Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim I…
|
+86 | 97 | 62k | 8mo |
|
Documenting a payment dispute without naming and shaming — the long version
Posting this under the heading it deserves: Documenting a payment dispute without naming and shaming — the long version Everything below is what sits behind that. I would like to talk about documentation…
|
2 | 32k | 1mo |